HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maria Banzi Selected Research

Colorectal Neoplasms (Colorectal Cancer)

12/2021Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.
1/2020Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
1/2020Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.
1/2019Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Maria Banzi Research Topics

Disease

8Colonic Neoplasms (Colon Cancer)
01/2021 - 12/2015
4Melanoma (Melanoma, Malignant)
12/2023 - 01/2016
4Colorectal Neoplasms (Colorectal Cancer)
12/2021 - 01/2019
3Neoplasms (Cancer)
11/2023 - 08/2013
2Brain Neoplasms (Brain Tumor)
12/2023 - 11/2021
2Disease Progression
11/2023 - 01/2021
1Hepatocellular Carcinoma (Hepatoma)
11/2023
1Obesity
01/2023
1Skin Neoplasms (Skin Cancer)
10/2022
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2021
1Mucinous Adenocarcinoma (Mucinous Carcinoma)
01/2020
1Human Influenza (Influenza)
01/2020
1Adenocarcinoma
01/2020
1COVID-19
01/2020
1Adenoma (Adenomas)
01/2019
1Hypophosphatemia
01/2019
1Fatigue
01/2019
1Diarrhea
01/2019
1Type 2 Diabetes Mellitus (MODY)
01/2019
1Chemical and Drug Induced Liver Injury
01/2019
1Hypertension (High Blood Pressure)
01/2019
1Microsatellite Instability
08/2013

Drug/Important Bio-Agent (IBA)

7Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021 - 12/2015
4dabrafenibIBA
12/2023 - 01/2016
3L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
12/2023 - 11/2021
3trametinibIBA
12/2023 - 11/2021
3Leucovorin (Folinic Acid)FDA Link
01/2020 - 12/2015
3Fluorouracil (Carac)FDA LinkGeneric
01/2020 - 12/2015
2Immune Checkpoint InhibitorsIBA
11/2023 - 01/2020
2regorafenibIBA
12/2021 - 01/2019
2Capecitabine (Xeloda)FDA Link
01/2020 - 01/2018
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2023
1130-nm albumin-bound paclitaxelIBA
01/2021
1GemcitabineFDA Link
01/2021
1Carcinoembryonic AntigenIBA
01/2019
1ErbB Receptors (EGF Receptor)IBA
01/2019
1Monoclonal AntibodiesIBA
01/2019
1Hypoglycemic Agents (Hypoglycemics)IBA
01/2019
1Metformin (Glucophage)FDA LinkGeneric
01/2019
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019
1Mitogen-Activated Protein KinasesIBA
01/2016
1VemurafenibIBA
01/2016
1Dihydrotachysterol (AT 10)IBA
12/2015

Therapy/Procedure

6Therapeutics
03/2023 - 08/2013
6Adjuvant Chemotherapy
01/2023 - 12/2015
5Drug Therapy (Chemotherapy)
01/2021 - 08/2013
1Immunotherapy
11/2023
1Contraindications
10/2022
1Combination Drug Therapy (Combination Chemotherapy)
01/2021
1Duration of Therapy
01/2020